Author | Lightnews

Guardant Health @guardanthealth.bsky.social · 5d

We have reported our third quarter 2025 financial results, highlighted by 39% year-over-year revenue growth.

Our continued momentum has led us to raise our full-year 2025 revenue guidance to $965–$970 million, representing 31% year-over-year growth.

Details: bit.ly/4nBoZaJ

Guardant Health @guardanthealth.bsky.social · 8d

We’re proud to announce a strategic partnership with
Zephyr AI to deliver novel, scalable, & actionable insights that support biopharma innovation, reflecting our shared commitment to leveraging AI and multimodal data to advance #CancerResearch and improve #PatientCare.

Guardant Health and Zephyr AI Announce Partnership to Unlock Drug Response Predictions and Biomarker Insights

Strategic partnership will link DNA data with rich clinical data to identify novel biomarkers for targeted cancer therapies The two companies will utilize AI and multimodal molecular data to unlock ne...

bit.ly

Guardant Health @guardanthealth.bsky.social · 8d

We're sharing data at #ACG2025, highlighting the critical role of blood-based testing in improving #CancerScreening adherence.

Data presentation details: bit.ly/4odIp6K

Guardant Health @guardanthealth.bsky.social · 12d

We’re excited to be at #JADPROLive in National Harbor, Maryland!

Stop by Booth #510 to meet our medical affairs team and explore the vital role oncology advanced practitioners play in advancing precision cancer care through molecular testing.

Guardant Health @guardanthealth.bsky.social · 14d

Innovations in cancer diagnostics are transforming the landscape of care.

The latest @milkeninstitute.org Institute report explores how liquid biopsies — noninvasive, blood-based tests — can revolutionize #CancerDetection and treatment.

Read more: bit.ly/4opJhVy

A Pivotal Role: Liquid Biopsies in the Future of Cancer Care | Milken Institute

Cancer care is entering a new era. Despite decades of investment and remarkable breakthroughs, the disease continues to affect millions of people each year—an

bit.ly

1 2

Guardant Health @guardanthealth.bsky.social · 18d

We’re excited to share our latest data this week at #ESMO25!

📍Visit us at Booth 3021 to learn more.

Additional details: bit.ly/4nVIQCu

1

Guardant Health @guardanthealth.bsky.social · Sep 29

We’re proud to share that the FDA has approved our Guardant360® CDx test as a companion diagnostic for
@elilillyandcompany.bsky.social's Inluriyo™ (imlunestrant)
for ESR1-mutated advanced #BreastCancer.

More details: investors.guardanthealth.com/press-releas...

1

Guardant Health @guardanthealth.bsky.social · Sep 16

We’re proud to be a partner of the World Clinical Biomarkers & Companion Diagnostics Summit next week.

Join our plenary session with Jean-Francois Martini to learn how our flexible solutions combined with multimodal real-world data and can streamline your #ClinicalDevelopment program for success.

1

Guardant Health @guardanthealth.bsky.social · Sep 15

We are proud to welcome Alex M. Azar II to our board of directors. Secretary Azar brings a unique perspective on the intersection of policy, innovation, and patient access that will help us advance our mission to conquer cancer with data.

Details: bit.ly/4gmjZom

1

Guardant Health @guardanthealth.bsky.social · Sep 8

Today we’re excited to announce a new partnership with
PathGroup to expand access to our Shield™ #BloodTest for early cancer detection.

Through PathGroup’s extensive network, Shield will soon be available in more than 250 hospitals and 15,000 physicians across 25 states.

Details: bit.ly/4peK392

1

Guardant Health @guardanthealth.bsky.social · Sep 5

On Tuesday, our Co-CEO Helmy Eltoukhy will join
@wired.com at #WIREDHealth for a featured conversation: “Winning the War on Cancer."

Helmy will explore how liquid biopsies are driving earlier detection, faster treatment decisions, & a more personalized patient experience.

Info: lnkd.in/e3KvKNsa

Guardant Health @guardanthealth.bsky.social · Aug 28

This past weekend, we teamed up with the Dolphins Cancer Challenge before the Dolphins took on the Jaguars to connect with fans and share more about Shield™, the blood test that screens for #ColonCancer the more pleasant way.

A big #ThankYou to all the fans who joined the conversation with us!

Guardant Health @guardanthealth.bsky.social · Jul 15

Today we announced that the 1st patient has been enrolled in the the National Cancer Institute's Vanguard Study, evaluating our Shield™ MCD test.

The 4-year study will assess the feasibility of using blood-based tests to detect multiple cancers in individuals w/o symptoms.

Details: bit.ly/40jXcms

Guardant Health @guardanthealth.bsky.social · Jul 8

Join us for a live #Webinar on the power of epigenomic biomarkers to improve patient selection and better predict treatment response in oncology clinical trials.

Register today: bit.ly/44kpIa3
📅 Date: July 24
🕘 Time: 9:00am PT

Guardant Health @guardanthealth.bsky.social · Jul 1

Last week, our co-CEO AmirAli Talasaz took the stage at #AspenIdeasHealth on the New Frontiers in Cancer panel, a timely discussion on how breakthroughs in blood-based screening, precision medicine, & AI are reshaping the future of care.

Watch the session: bit.ly/4kt5yQ0

Photo credit: Leigh Vogel

Guardant Health @guardanthealth.bsky.social · Jun 30

At #AspenIdeasHealth, our co-CEO AmirAli Talasaz sat down with @drjohntorres.bsky.social to discuss a critical gap in cancer care: screening technologies are advancing, but access isn’t keeping pace.

Guardant Health @guardanthealth.bsky.social · Jun 10

Exciting news! Our Shield™ blood test has been recognized on @fastcompany.com's 2025 World Changing Ideas list! We're thrilled to be part of this amazing collection of ideas driving meaningful change in the world.

Check out the full list here: fastcompany.com/world-changi...

#FCWorldChangingIdeas

1 2

Guardant Health @guardanthealth.bsky.social · Jun 9

Today, we’re proud to share that ESMO Open has published results from the LIBERATE study, highlighting Guardant Reveal’s performance in detecting minimal residual disease in early-stage #BreastCancer.

Details: bit.ly/43yOanC

Guardant Health @guardanthealth.bsky.social · Jun 3

We're honored to announce that our Shield multi-cancer detection (MCD) test has been granted Breakthrough Device designation from the @fda.gov.

More details: investors.guardanthealth.com/press-releas...

Guardant Health @guardanthealth.bsky.social · Jun 2

Featured in @nytimes.com: Our Guardant360® CDx test is helping revolutionize #BreastCancer treatment by detecting drug resistance before it shows up on scans—enabling timely treatment changes and improving patient outcomes.

Drug-Defying Breast Cancers Spotted Early in Blood Test Study

www.nytimes.com

Guardant Health @guardanthealth.bsky.social · Jun 2

We’re proud to share that the National Comprehensive Cancer Network has included our Shield™ blood test in its updated #ColorectalCancer screening guidelines. Marking a pivotal step forward in expanding #PatientAccess to an innovative, blood-based screening option.

Details: bit.ly/3SxrayX

Guardant Health @guardanthealth.bsky.social · Jun 2

Today we announced results from the Phase III SERENA-6 trial, demonstrating the clinical value of our Guardant360® CDx test in detecting & treating emerging resistance in advanced #BreastCancer ahead of radiological progression.

Details: bit.ly/4mJ3kxU

1

Guardant Health @guardanthealth.bsky.social · Jun 1

The future of precision oncology is here.

Join us at #ASCO25, booth #25077, to discover the pivotal role of liquid biopsy in transforming cancer care and improving patient outcomes.

Guardant Health @guardanthealth.bsky.social · May 31

At #ASCO25 yesterday, we shared results from the largest study to date evaluating ctDNA in #ColonCancer, highlighting the power of our Guardant Reveal™ test to inform critical treatment decisions.

More details: bit.ly/4mFFHq1

1

Guardant Health @guardanthealth.bsky.social · May 29

Join us at #ASCO25 for an exclusive event showcasing how our Guardant Infinity™ platform is propelling patient-centered care into the future. Discover how redefining precision oncology through innovation & advocacy.

📅 Monday, June 2
🕗 8 AM–5 PM
📍 Marriott Marquis Chicago | Astronomy Room